RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:So far so good Thank you Wino, that is some pretty encouraging stats, gives us something else to hold onto while patiently waiting.... Well, it's happy hour where my wife and I are and we need to work on the overbought Pandemic/apocalypse wine stash before they go bad ;->
Wino115 wrote: Correct for the percentage gain seen. Moving a molecule up from pre-clinical to successful Phase 1 sees largest % gains, they continue through to Phase 2 and into commercialization but the law of large numbers catchs up on the market cap eventually. As we all know, it's easier for a $400mil mkt cap to double or triple versus a $2bil market cap.
I believe it is FTV that had a target around $5 going in to AACR or thereabouts, then he had $7 for post AACR and in to any early data or NASH protocol. Then if I recall, $15 for end of year or something like that. So much depends on the hard data, although NASH is just about moving the pipeline into Phase 3. Nonetheless, we've seen nice price action, rather choppy volumes, but I think as the crowd around it is built up with both the retail learning about it and hopefully spreading to institutions via the new shareholders bringing a crowd, we see larger steady volumes at increasing prices -- hopefully not like these crazy spikes on limited volume which always fade. Nice sustained gains at a measurable pace, supported by facts. That's what I want.
Lee430 wrote: This going to seem rudimentary to most or all, but I was thinking if Thera could somehow hold above $4 US and $5 CAD before some positive news at AACR & 2Q21 it would make it so much easier to move up a significant amount then, dare I say hold some of the gains…I believe Wino mentioned that a large part of the SP gains is made during PH1 trials if I remember that correctly.
qwerty22 wrote: I think the point everybody is making is that taking multiple opportunities to explain those simple ideas is a good thing. This happens to be the biggest oncology conference in the world. It attracts the attention of the whole of the biotech investing industry. There is a lot of competition from biotech to be seen. Either you can try to make your presence felt on you can stay on the sidelines. The cancer program is very early but it has already made some great advances (fast track) and it is at an exciting stage. It seems like a perfect opportunity to try to get an audience and honestly talk about what THTX has, I think that is all people want.
jfm1330 wrote: Here are links to the two abstracts. There is nothing fundamentally new in these abstracts. They prove overexpression of sortilin receptor, the affinity of their peptide to sortilin (it means their peptide binds with sortilin), and they show in vivo effect on animal models in cancer types they did not tested before. Nothing to do a webcast about. The basic principles for non scientific investors can be explained very quickly and are easy to understand. It works on xenograft of selected cancer tumor in mice. We already knew that. The big question is will it work on a real heterogenous tumor (not a selected one) in the human body, with human enzymes to degrade the PDC, etc.. If I would be in the places of Levesque and Marsolais I would not sound overly optimistic in April, only to look like a fool, or a crook a few months later id it does not work on human. Thera is an honest company, not Cytodyn.
https://www.abstractsonline.com/pp8/#!/9325/presentation/2039
https://www.abstractsonline.com/pp8/#!/9325/presentation/2111